## Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims

Claims 1-21. (Canceled)

- 22. (Original) A method of treating or preventing restless leg syndrome which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, clathrate, or produrg thereof.
- 23. (Original) The method of claim 22 wherein the sibutramine metabolite is optically pure.
- 24. (Original) The method of claim 23 wherein the sibutramine metabolite is (R)-desmethylsibutramine, (S)-desmethylsibutramine, (R)-didesmethylsibutramine, or (S)-didesmethylsibutramine.
- 25. (Original) The method of claim 22 which further comprises the administration of pergolide, carbidopa, levodopa, oxycodone, carbamazepine, or gabapentin, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, optically and pharmacologically active stereoisomer, or pharmacologically active metabolite thereof.

Claims 26-40. (Canceled)

- 41. (New) The method of claim 22, wherein the amount of sibutramine metabolite administered is from about 0.1 mg to about 60 mg/day.
- 42. (New) The method of claim 41, wherein the amount of sibutramine metabolite administered is from about 2 mg to about 30 mg/day.

- 43. (New) The method of claim 42, wherein the amount of sibutramine metabolite administered is from about 5 mg to 15 mg/day.
- 44. (New) The method of claim 22, wherein the sibutramine metabolite is administered orally, mucosally, rectally, parenterally, transdermally or subcutaneously.
- 45. (New) The method of claim 44, wherein the sibutramine metabolite is administered orally, mucosally or transdermally.